Pulmonary fibrosis Accueil Human and animal health In vivo Inflammation Pulmonary fibrosis In vivo Inflammation Our models for Human and animal health In vitro/ex vivo cytotoxicity Cytotoxic activity - 2D cell Cytotoxic activity - 3D human tissue Cytotoxic activity - human organoid Hemolysis assay In vivo safety Maximum tolerated dose Pharmacokinetics In vitro/ex vivo testing Antiviral drug screening evaluation 3D tissue CC50 / IC50 assay Cytopathic effect inhibition assay Elisa Based assays Immune cells quantification Lung organoids Virus yield reduction Virus/antibody related assay Custom virus production service Microneutralization assay Plaque reduction assay qPCR assay TCID50 assay Antibacterial and antifungal 3D tissue Anti-biofilm activity Antimicrobial susceptibility testing Antimicrobial synergy testing Bacterial genome editing Bacterial susceptibility to bacteriophages CC50 / IC50 assay Drug resistance strain isolation and identification Extracellular vesicles in pathophysiology Immune cells bactericidal assay Intracellular bacteria Lung organoids Mechanism of action - envelop integrity Minimum bactericidal concentration Minimum doubling time Minimum inhibitory concentration Persisters Resistance development Taylor-made ELISA Development Time kill Curve (TKC) Turbidity reduction assay In vivo Bacterial/fungal infection Gastrointestinal infection models Pulmonary infection models Septicemia models Skin infection models Thigh infection models Urinary tract infection models Viral infection Pulmonary infection models Septicemia models Inflammation DSS LPS Pulmonary fibrosis Quickly qualify your study needs Go !
